Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial

Calandre, Elena P.; Rico‐Villademoros, Fernando; Galan, J.L.; Molina-Barea, Rocío; Vilchez, J.S.; Rodriguez-Lopez, C.M.; Hidalgo‐Tallón, Javier; Morillas-Arques, Piedad

doi:10.1007/s00213-013-3422-0

Cited by 39 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A statistical analysis indicated that quetiapine had failed to prove non-inferiority compared to amitriptyline. Moreover, 51% of the subjects in the quetiapine arm of the study withdrew prior to completion, mostly due to adverse effects [16]. In an earlier smaller study quetiapine or placebo (NCT00983320) was added to other pharmacologic treatments for FMS.…”

Section: Quetiapinementioning

confidence: 99%

Recent strategies for drug development in fibromyalgia syndrome

Blumenthal

Malemud

2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

The US Federal Drug Administration (FDA) approved 3 medications for treating fibromyalgia syndrome (FMS). There have been no additional FDA approvals since January 2009 and the efficacy of the FDA-approved medications for FMS has been questioned. Areas covered: The "search for studies" tool using clinicaltrials.gov and PubMed were employed. The term, "fibromyalgia" was used for clinicaltrials.gov. The terms employed for PubMed were "Name-of-Drug Fibromyalgia", "Fibromyalgia Treatment" or "Fibromyalgia Drug Treatment." Clinical trials were reviewed if they were prospective and blinded, and if they employed a comparator, either placebo or another pharmaceutical. Expert commentary: Progress toward standardizing the outcome measures for FMS clinical trials have been made but challenges remain. Several pharmaceutical candidates for FMS have been tested since 2009. The results of these studies with potential novel targets for drug development for FMS were reviewed including the results of trials with sodium oxybate, quetiapine, esreboxetine, nabilone, memantine, naltrexone, and melatonin.

show abstract

Section: Quetiapinementioning

confidence: 99%

Recent strategies for drug development in fibromyalgia syndrome

Blumenthal

Malemud

2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Potential clinical benefits include an analgesic effect, anxiety reduction, and establishment of normal sleep patterns, all of which are associated with and worsen FGID symptoms including pain. Most data stems from the treatment of fibromyalgia where recently a controlled study reported effects superior to placebo on the pain‐domains, but with effects inferior to duloxetine in yet another recent study . A major drawback is poor tolerability with a high proportion of patients experiencing sedation, dizziness and weight gain leading to discontinuation of treatment when used in the higher dose ranges of 100–300 mg/day.…”

Section: Augmentation Treatmentmentioning

confidence: 99%

Centrally targeted pharmacotherapy for chronic abdominal pain

Törnblom

Drossman

2015

Neurogastroenterology Motil

View full text Add to dashboard Cite

A conceptual model of predisposing, precipitating, and perpetuating factors is used to explain how a situation of chronic pain develops and it provides the evidence for central neuron degeneration as relevant to this chain of events. The rationale for centrally targeted medications, in particular antidepressants, is discussed with regard to effects independent of their role in treating psychiatric disorders: with regard to downregulation of afferent pain signals and their potential role in neuron proliferation. Finally, guiding examples of which drug to use and treatment combinations involving multiple drugs, augmentation treatment, are outlined and some brief clinical cases of centrally targeted pharmacotherapy.

show abstract

“…Amitriptyline was found to reduce the FIQ questionnaire results from baseline to endpoint by over 30% [48][49][50]. It was found to improve pain, fatigue, sleep, and quality of life [11].…”

Section: Tricyclic Antidepressants (Tcas) Although Differentmentioning

confidence: 98%

Current and Emerging Pharmacotherapy for Fibromyalgia

Tzadok

Ablin

2020

Pain Research and Management

View full text Add to dashboard Cite

Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.

show abstract

Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial

Abstract: Our results appear to indicate that quetiapine XR does not provide similar efficacy to amitriptyline for treating patients with fibromyalgia. Quetiapine XR had a worse tolerability than amitriptyline in this population, possibly due to a relatively high starting dose.

Cited by 39 publications

References 19 publications

Recent strategies for drug development in fibromyalgia syndrome

Recent strategies for drug development in fibromyalgia syndrome

Centrally targeted pharmacotherapy for chronic abdominal pain

Current and Emerging Pharmacotherapy for Fibromyalgia

Contact Info

Product

Resources

About